Lineage Cell Therapeutics (LCTX) Equity Average (2011 - 2026)

Lineage Cell Therapeutics has reported Equity Average for 16 years, with the latest figure at $48.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 37.14% year-over-year to $48.6 million; the trailing twelve-month figure through Mar 2026 stood at $48.6 million (down 37.14% YoY), and the FY2025 full-year result was $60.2 million, down 13.43% from the prior year.
• Equity Average for Q1 2026 stood at $48.6 million, up from $32.7 million in the prior quarter.
• The five-year high for Equity Average was $88.1 million in Q1 2022, with the low at $32.7 million in Q4 2025.
• Historically, Equity Average has averaged $66.3 million across 5 years, with a median of $69.0 million in 2023.
• The largest YoY upside for Equity Average was 16.28% in 2025 against a maximum downside of 53.89% in 2025.
• Lineage Cell Therapeutics' Equity Average stood at $74.7 million in 2022, then dropped by 13.92% to $64.3 million in 2023, then increased by 10.2% to $70.9 million in 2024, then slumped by 53.89% to $32.7 million in 2025, then soared by 48.69% to $48.6 million in 2026.
• The last three Equity Average figures came in at $48.6 million (Q1 2026), $32.7 million (Q4 2025), and $34.6 million (Q3 2025), per Business Quant data.